anti-CD19/BCMA CAR T-cell therapy (AbelZeta)

N/A

Report date: 2025/06/11 11:18:11

Base Information

Drug Nameanti-CD19/BCMA CAR T-cell therapy (AbelZeta)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsTumor necrosis factor ligand superfamily member 13 modulators +[4]

TargetsB-lymphocyte antigen CD19Tumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbelZeta Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbelZeta Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A